Compositions, Methods and Kits for Diagnosis of Lung Cancer
AssigneeIntegrated Diagnostics, Inc.
InventorsPaul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
Life of this patent
Estimating the term…
Abstract
Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC)
Claims36
A method of determining the likelihood that a lung condition in a subject is cancer, comprising:
- (a) measuring an abundance of a panel of proteins in a sample obtained from the subject, wherein said panel comprises at least 3 proteins selected from the group consisting of ALDOA, FRIL, LG3BP, IBP3, LRP1, ISLR, TSP1, COIA1, GRP78, TETN, PRDX1 and CD14;
- (b) calculating a probability of cancer score based on the protein measurements of step (a);
- and
- (c) ruling out cancer for the subject if the score in step (b) is lower than a pre-determined score.
A method of ruling in the likelihood of cancer for a subject, comprising:
- (a) measuring an abundance of panel of proteins in a sample obtained from the subject, wherein said panel comprising at least 3 proteins selected from the group consisting of ALDOA, FRIL, LG3BP, IBP3, LRP1, ISLR, TSP, COIA1, GRP78, TETN, PRDX1 and CD14;
- and
- (b) calculating a probability of cancer score based on the protein measurements of step (a);
- and
- (c) ruling in the likelihood of cancer for the subject if the score in step (b) is higher than a pre-determined score.
A method of determining the likelihood of the presence of a lung condition in a subject, comprising:
- (a) measuring an abundance of panel of proteins in a sample obtained from the subject, wherein said panel comprising at least 3 proteins selected from the group consisting of ALDOA, FRIL, LG3BP, IBP3, LRP1, ISLR, TSP, COIA1, GRP78, TETN, PRDX1 and CD14;
- (b) calculating a probability of cancer score based on the protein measurements of step (a);
- and
- (c) concluding the presence of said lung condition if the score determined in step (b) is equal or greater than a pre-determined score.
Dependencies are inferred from the claim text.